‘The main aim of European Hormone Day is to remind politicians about the importance of good hormone health in European health policies and to build awareness among the public at large.’

Martin Reincke
ESE President
Who we are

The **European Society of Endocrinology** (ESE) is at the centre of Europe’s endocrine community, representing over 22,500 endocrinologists across the continent. Our wide inclusion of diverse, innovative communities is our strength.

We are shaping the future of endocrinology – the study of hormones – to improve science, knowledge and health throughout Europe and beyond. The Society’s new five-year strategy for 2022–2026 helps ESE drive better medical outcomes for patients by:

- **UNITING and REPRESENTING** the European endocrine community and being acknowledged as the reference point for endocrine health and science
- **SUPPORTING** our members in education, clinical practice and research
- Further **ADVANCING** the science and clinical care of endocrinology
- Reinforcing ESE as a leading society which is **SUSTAINABLE, TRUSTED AND VALUED**

### Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td><strong>Welcome from the President</strong></td>
</tr>
</tbody>
</table>
| 4-5  | **Uniting and representing**  
Working with others  
European Hormone Day  
Endocrine Research Roadmap  
European Women in Endocrinology  
Standing with Ukraine  
Supporting patient groups |
| 6-7  | **Supporting our members**  
Understanding members’ needs  
Advancing endocrine nursing  
Providing financial support  
Enhancing early careers  
Resources for researchers  
A forum for opinion and debate |
| 8-9  | **Advancing endocrinology**  
ECE 2022 – our first hybrid Congress  
Education and training  
ESE’s peer-reviewed journals |
| 10-11| **Being sustainable, trusted and valued**  
ESE Executive Committee  
Planning for the future  
Policies for equality and the environment  
Meet the ESE Team  
Thanks to our Corporate Members |
| 12-13| **Treasurer’s report and accounts** |
| 14   | **Recognising excellence**  
Award winners 2022 |

### Headslines for 2022

- **European Hormone Day** launched to raise awareness
- **5166 ESE members**: a record number
- **First hybrid ECE** reaches 4000 attendees
- **Equality, diversity and inclusion at the centre of ESE activities**

---

**Abbreviations used**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECAS</td>
<td>ESE Council of Affiliated Societies</td>
</tr>
<tr>
<td>ECE</td>
<td>European Congress of Endocrinology</td>
</tr>
<tr>
<td>EJE</td>
<td>European Journal of Endocrinology</td>
</tr>
<tr>
<td>Endo-ERN</td>
<td>European Reference Network on Rare Endocrine Conditions</td>
</tr>
<tr>
<td>ESE</td>
<td>European Society of Endocrinology</td>
</tr>
<tr>
<td>ESPE</td>
<td>European Society for Paediatric Endocrinology</td>
</tr>
<tr>
<td>EUWIN</td>
<td>European Women in Endocrinology</td>
</tr>
<tr>
<td>EYES</td>
<td>ESE Young Endocrinologists and Scientists</td>
</tr>
<tr>
<td>EYES COP/ROP</td>
<td>EYES Clinical/Research Observership Programmes</td>
</tr>
</tbody>
</table>
Welcome

A year of progress

2022 was a year of new developments for the Society, as we stepped out from the shadow of the pandemic and moved keenly towards normality.

January was the perfect time to embrace our new, comprehensive strategy for 2022–2026, just as the world was also making a fresh start. The layout of this Annual Review reflects the four pillars of ESE’s plan for the future (www.ese-hormones.org/about-us):

• to unite and represent the European endocrine community
• to support our members
• to advance the science and clinical care of our discipline
• to be sustainable, trusted and valued.

As you read on, you will be enthused and excited by the amount we have achieved in just one year, and by the prospect of what the next four years will bring.

Working with others is a cornerstone of our approach to meeting these goals. A new Specialist Societies Task Force has made great progress in establishing strong collaborations with several societies in key areas of our work (see page 4).

Striving for equality, inclusion and diversity is also essential in maximising the potential of any organisation. A key objective of my presidency has always been to stay true to our values and improve the level of equality and diversity within ESE. Our new policy in this area (see page 11) heralded the first year of open calls for committee nominations, and we welcomed the new group ‘European Women in Endocrinology’ (see page 5).

ESE’s will to enact this policy is captured in our new ‘The Way that We Work’ statement: ‘We aspire to be visionary, inspiring, engaging and supportive. We are open, transparent and inclusive in everything that we do, and work towards diversity across our activities.’

Implementing a new in-house customer relationship management system during 2023 will allow us to track our progress in achieving equality, diversity and inclusion. This is just one part of the planned expansion of ESE’s staffing and infrastructure to support our new strategy.

In this same spirit of supporting the entire breadth of our membership, 2022 saw enhanced activities for basic scientists in endocrinology. The re-establishment of Summer School was accompanied by new PhD grants to support attendance. We also reformatted the ESE-SEEDER-EU programme to provide consultancy support, and continued our very successful Spotlight on Science series (see pages 7 and 8). Importantly, work on the new European Research Roadmap has begun (see page 5).

The launch of European Hormone Day, the dedicated annual hormone awareness day, was a major new undertaking for ESE, along with the European Hormone and Metabolism Foundation (the ESE Foundation). Its aim is to alert policymakers and the public to hormones’ central role in health and in addressing disease (see page 4). The day also saw the launch of the Milano Declaration, summarising challenges and potential solutions in our field. The ESE Council of Affiliated Societies was central to drafting the declaration, which was endorsed by 9 MEPs, 40 societies and 15 patient advocacy groups.

Regrettably, no review of 2022 is complete without mention of the situation faced by our colleagues in Ukraine. ESE was eager to offer immediate support. The ESE Task Force Ukraine was established and continues to hold regular meetings to discuss activities where ESE can continue to help (see page 5).

I thank everyone who has played a part in supporting ESE and achieving the phenomenal progress we have made in 2022. I feel deeply moved by the evident passion for and dedication to our Society, and I am honoured to be the President of this organisation.

Martin Reincke
ESE President
Twitter: @EsePresident

of attendees chose to interact with the Congress online. Meanwhile, we saw increased five-year Impact Factor values for both of ESE’s journals, achieving new highs.

ECE 2022: ESE’s first hybrid Congress. Delegates had the opportunity to attend in person or virtually, an approach which increased the event’s accessibility. Almost 30%
Unifying and representing

ESE brings the European endocrine community together and is recognised as the reference point for endocrine health and science.

Working with others

ESE increased close collaboration with partners in key areas, especially topics highlighted in the ESE 2021 White Paper: ‘Hormones in European Health Policies: How endocrinologists can contribute towards a healthier Europe’ (www.ese-hormones.org/whitepaper).

Our work with the European Association for the Study of Obesity focused on the endocrine aspects of this disease, across prevention and treatment.

In the field of endocrine-disrupting chemicals (EDCs), ESE representatives addressed the 4th Annual Forum on Endocrine Disruptors and the annual meeting of EDC-Free Europe (a coalition of more than 70 public interest groups). The Society provided expert input into consultations on both REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) and CLP (Classification, Labelling and Packaging), and acted in partnership with the European Society for Paediatric Endocrinology (ESPE), the European Thyroid Association and the Endocrine Society, to express concerns over the delayed REACH revision.

We liaised with Endo-ERN and ESPE to produce our ESE Talks ... Rare Diseases series of webinars (see page 8). We also began work on joint guidelines with the Endocrine Society, to address corticosteroid therapy (led by ESE) and diabetes in pregnancy (led by the Endocrine Society).

Our membership of the European Cancer Organisation and BioMed Alliance reflected ESE’s continuing commitment to promoting excellence in European biomedical research and patient care.

Joint sessions at ECE 2022 also saw ESE collaborate with a wide range of partner societies.

Getting hormones noticed

ESE, working alongside the European Hormone and Metabolism Foundation (ESE Foundation), launched European Hormone Day on 23 May 2022. This is an annual event to alert policymakers and the public to hormones’ central role in health and in addressing disease.

Challenges and potential solutions in endocrinology were summarised in ‘Recognising the key role of hormones in European health: the Milano Declaration’, which was issued on European Hormone Day.

The ESE Council of Affiliated Societies (ECAS) was central to drafting the declaration, which encourages policymakers to integrate an endocrine perspective into health policies, nationally and across Europe.

See www.ese-hormones.org/ehd-milano-declaration

‘It is pivotal that through effective policy and regulatory measures we phase out bisphenol A from our daily life.’

Joint statement with the Endocrine Society

‘I fully support this important initiative and the recommendations of the Milano Declaration. We should raise awareness of the importance of hormone health!’

Ewa Kopacz
Vice-President of the European Parliament
Lighting the way for science

With its partner societies, ESE began work on an Endocrine Research Roadmap, which will identify the priority research needs of basic science, translational and clinical experts in endocrinology across Europe. Highlighting these priorities to policymakers and funding bodies will enable them to be addressed in future research calls and funding programmes, ultimately improving endocrine health.

See www.ese-hormones.org/roadmap

Improving opportunities for women

ECE 2022 saw the launch of European Women in Endocrinology (EUWIN). This peer-to-peer support community was set up by ESE in collaboration with its founders (right): Cynthia Andoniadou (UK), Jenny Visser (The Netherlands) and Wiebke Arlt (UK).

EUWIN will improve opportunities for women, for example by enhancing networking, mentoring and support for female trainees and investigators, and those returning to work following a career break. We gathered ideas from ESE members at the EUWIN launch and via the ESE membership survey to develop a plan which reflects the support that women in endocrinology need.

See www.ese-hormones.org/euwin

Standing with Ukraine

ESE worked with Boris Mankovsky of the Ukrainian Diabetology Association and Oksana Khyzhnyak of the Ukrainian Association of Paediatric Endocrinology to form the ESE Task Force Ukraine, which enabled us to support our Ukrainian colleagues by:

- identifying shortages of essential endocrine drugs
- mapping 40 endocrine specialist centres to support refugee patients
- sharing patient information in Ukrainian and Russian
- providing emergency cards for endocrine conditions in Ukrainian/Russian and English
- giving free ESE membership and educational benefits to Ukrainian and Moldovan colleagues.

ESE now has 24 Patient Advocacy Group Affiliate Members, who benefit from support to help them achieve their objectives. They met for the first time at a session during ECE 2022.

See www.ese-hormones.org/patient-advocacy-group

Supporting patient groups

ESE also set up a pilot project, the Hypoparathyroidism Patient Forum, to bring together clinical experts and patient group representatives from across Europe to understand patient needs. The first patient forum event attracted 175 virtual attendees, including patients, families, carers and clinicians.

See www.ese-hormones.org/for-patients/hypoparathyroidism-patient-forum
Supporting our members

We work to meet the needs of our members in education, clinical practice and research.

Who are our members?

- 5166 members
- 59% national affiliate members
- 48% female
- 36% male
- 32% early career members

Understanding members’ needs

ESE surveyed members to better understand their needs and to support recruitment, retention and engagement.

- 98% of members said they planned to still be a member in a year’s time
- 95% of members felt their membership was good value for money

Clinicians identified access to ESE journals as the most important membership benefit, while scientists particularly value reduced-price fees for events. Nurses also rated reduced attendance fees, as well as access to educational opportunities and clinical guidelines.

Advancing endocrine nursing

Endocrine nurses benefited from a half-day pre-Congress session and a full-day session during ECE 2022. This attracted over 90 attendees.

Cecilia Folin (Sweden, pictured) was chosen as the inaugural recipient of the ESE Endocrine Nurse Award, which she will receive at ECE 2023.

To increase engagement and boost Nurse Membership, the ESE Nurse Committee sent representatives to national endocrine nursing group meetings in China, Italy and Sweden.

Nurturing our community

This special logo was produced for our valued National Affiliated Societies and Patient Advocacy Group Affiliated Members, to reflect their important role in the ESE community.
Providing financial support

ESE grants are available to all our members, but we are particularly keen to support the early career community. In 2022, 40% of our grants were received by members under the age of 30 (an increase from almost none five years ago). Two-thirds of all our grant recipients were female.

>240 grants to ESE members in 2022
Total awarded >€150 000
71% of recipients were ≤40 years old

Enhancing early careers

The 9th ESE Young Endocrinologists and Scientists (EYES) Meeting in Zagreb, Croatia, was the first EYES Meeting to take place in person since 2019. Over 150 participants were present, from 22 countries, and James Wilmouth Jr (France) won the prize for best abstract.

The well-attended EYES Symposium at ECE 2022 in Milan, Italy, featured experts talking on challenges in male infertility research.

EYES News is the magazine dedicated to ESE’s early career members. Walter Vena (Italy) took on the role of Editor from Antoan Stefan Sojat (Serbia); both have succeeded in enhancing the magazine’s topical and diverse content. See www.ese-hormones.org/eyesnews

Supporting the research community

The ESE SEEDER-EU grant has a new format, and now provides consultancy support for scientists to apply for European research funding. Expert advice is available on various aspects of the application process. See www.ese-hormones.org/ese-seeder-eu-grant

The newly developed ESE EU Research Funding Information Hub offers guidance on the latest EU funding opportunities. See www.ese-hormones.org/european-research-funding-programmes

2022 saw the return of ESE Summer School and more Spotlight on Science sessions, enhancing ESE’s training provision for basic scientists (see page 8). The Endocrine Research Roadmap will identify priority research areas for future funding (see page 5).

Stimulating opinion

ESE’s membership magazine, Endocrine Views, established itself as a forum for topical opinion. Leading articles addressed subjects such as the issues underlying gender equality and efforts to change the management of obesity.

See all past issues at www.ese-hormones.org/news
Advancing endocrinology

ESE progresses endocrine science and clinical care, through collaboration, education, communication and engagement.

Meeting and sharing

ECE 2022 – the 24th European Congress of Endocrinology – in Milan, Italy, was ESE’s first hybrid Congress, with attendance in person or virtual. This approach successfully increased the reach of the Congress, with almost 30% of delegates attending online.

Delegates represented the breadth of ESE’s Focus Areas, as well as a wide geographical spread. ECE 2022 saw the launch of European Hormone Day (see page 4) and European Women in Endocrinology (see page 5).

Learning together

ESE supports the development of endocrinologists and scientists at all career stages and in every aspect of the field. Events in 2022 were conducted online and in person, to benefit the maximum number of people.

Five informal, free ESE Spotlight on Science masterclasses for basic scientists covered diverse research topics in endocrinology and metabolism, with an average of 110 attendees at each session.

See www.ese-hormones.org/ese-courses/ese-spotlight-on-science

ESE Summer School, in Innsbruck, Austria, was attended by 40 early career endocrine scientists. It was long-awaited, having originally been scheduled for 2020.

The 10th anniversary of EuroPit in Annecy, France, brought together 29 young doctors in endocrinology, neurosurgery and pathology for 3 days working closely with experts in pituitary disease. Chair Jacqueline Trouillas was thanked for her inspiring role (pictured).

See www.ese-hormones.org/ese-courses/europit-2022

Two Clinical Updates for clinical trainees, each comprising three 2-hour webinars, covered prolactinomas (129 attendees) and calcium and bone (103 attendees). Clinical endocrinologists also benefited from two Postgraduate Training Courses, the first online (170 attendees), and the second with 120 attendees online and 138 in person in Tbilisi, Georgia.

Our ESE Talks ... Rare Diseases series included two joint webinars from ESE, EndoERN and ESPE. The first discussed transition in pituitary disorders (176 attendees), and the second focused on a holistic approach in MEN1 management (188 attendees).

See www.ese-hormones.org/education/ese-talks
Communicating high quality research

ESE’s peer-reviewed journals continued to publish high quality research and reviews by ESE members and others. This was reflected by a sustained upward trend in their five-year Impact Factors: European Journal of Endocrinology (EJE) reached 6.805 and Endocrine Connections 3.635.

- 179 articles published in 2022
- 1112 submissions (16% accepted)
- 246 submissions from ESE members (33% accepted)

The latest ESE Clinical Practice Guideline, ‘Endocrine–related adverse conditions in patients receiving immune checkpoint inhibition’ by Eystein Husebye and colleagues, was published in EJE. See https://doi.org/10.1530/EJE-22-0689

Pia Burman and collaborators published an update of ESE’s 2016 Aggressive Pituitary Tumour Survey, addressing unanswered questions by means of a second survey. See https://doi.org/10.1530/EJE-22-0440

EJE Rising Stars

The new EJE Rising Stars programme supports clinical and translational endocrine researchers, who have great potential to serve as Editors of EJE.

Benefits include two years on the EJE Rising Star Reviewer Board, a mentorship programme, an ECE travel bursary and invitation to the EJE Editorial Board meeting.

Our first recipients were (from left to right): Sophie Bensing (Sweden), Avivit Cahn (Israel), Guido Di Dalmazi (Italy), Tim Korevaar (The Netherlands), Dan Niculescu (Romania), Svenja Nölting (Switzerland), Michael O’Reilly (Ireland), Cristina Olarescu (Norway), Nadia Schoenmakers (UK), Roland Stimson (UK), Elena Valassi (Spain), Dimitra Vassiliadi (Greece) and Maria Yavropoulou (Greece).

See https://academic.oup.com/ejendo/pages/rising-stars

High-ranking Impact Factors

European Journal of Endocrinology 6.558
Endocrine Connections 3.221

*Two-year Impact Factor values

ESE members continue to receive free online journal access, reduced rates on print subscriptions and discounts on open-access publication fees.

We thank our authors, reviewers, readers and Editorial Boards, who ensure that ESE journals are the best places to publish world-class endocrinology. Special thanks go to our Editors-in-Chief, Wiebke Arlt and Adrian Clark (pictured below).
These three qualities underpin all aspects of our work in endocrinology.

Led by endocrinologists

Our Executive Committee provides broad experience and strong collaboration. We thank them all, especially those who completed their terms of office in 2022. We welcome our new members.

Planning for the future

Setting ESE’s new strategy for 2022–2026 involved careful consultation between the Executive Committee and members of the Society’s Committees and Task Forces, the Focus Area Leads and others within our community, including ESE members and patient groups.

The strategy’s overriding aim is to continue to progress our vision of shaping the future of endocrinology, to improve science, knowledge and health.

See www.ese-hormones.org/about-us
Sharing our values

ESE has developed an **Equality, Diversity and Inclusion Policy**, which demonstrates our commitment to avoiding discrimination and promoting equality of opportunity. We have implemented **open calls for committee membership**, encouraging any ESE member to nominate themselves or another member for a role on a committee, working group or editorial board, etc.

Within our committees, we aim to achieve balance in gender, age/career stage, geographic and ethnic representation and in the different areas within endocrinology, for clinicians, clinician scientists, scientists, nurses and allied health professionals. **We encourage recruitment from groups that are currently under-represented.** Our new data management system will enable us to monitor the success of this policy more effectively.

Our new **Environmental Policy** acknowledges the growing impact of our activities on the environment and our responsibility to manage this and to work closely with our suppliers in this respect. Further policy development is planned.

ESE recognises the dedication of our volunteers who contribute their expertise and time when attending meetings on our behalf, and we have updated our **Travel and Expenses Policy**.

See [www.ese-hormones.org/about-us/our-policies](http://www.ese-hormones.org/about-us/our-policies)

Building our team

ESE has expanded the Society’s team, to support our new strategy for 2022–2026.

L–R: **Natalie Dass** Business Development Manager  
**Mischa van Eimeren** EU Liaison Officer  
**Victoria Withy** Sales and Marketing Manager  
**Andrea Davis** Governance and Office Manager  
**Helen Gregson** Chief Executive Officer  
**Vicki di Guisto** Scientific Programmes Manager  
**Magdalena Klimontowska** Scientific Programmes Project Manager  
**Dirk de Rijdt** Director of Strategic Partnerships  
**Janice Clay** Senior Marketing Executive  
**Claire Arrigoni** Event Manager  
Not present:  
**Louise Downey** Governance Officer  
**Leonie van Hulsteijn** Methodologist  
**Srđan Pandurević** Scientific Programmes Project Manager

Valuing our corporate supporters

We are grateful for the continued support of our 2022 Corporate Members, which increases the range of events and activities that ESE is able to offer our members.

**ESE Premium Corporate Members:** Ipsen, *Novo Nordisk, Pfizer, Recordati Rare Diseases, Takeda*  
**ESE Corporate Members:** *Abiogen, Diurnal, HRA Pharma Rare Diseases, Kyowa Kirin International, Uni-Pharma*  
**ESE Supporters:** Crinetics Pharmaceuticals, Soleno Therapeutics

*New for 2022*
To be successful in shaping the future of endocrinology and advancing the field, ESE’s strategy is to establish financial sustainability and develop excellent commercial relationships with a long term perspective.

Treasurer’s report

In 2022, there was a move out of the pandemic and a return to face-to-face meetings and interactions. This included in-person attendance at our Congress in Milan and at many of our courses. Although ESE had performed well financially throughout the pandemic, it was essential that we continued to focus on ensuring the Society was in good financial shape, in the face of financial challenges.

Financial headlines 2022

- The outcome from 2022 was an operating deficit of €353,950, which was foreseen and budgeted. 2022 was a difficult year for the stock market and, despite ESE’s medium–low risk approach to investments, there was a loss on investments of €697,159. Including investments, there has therefore been a reduction of €1,051,109 in the organisational value of ESE to €5,325,853, including restricted funds (2021: €6,376,961). There was a surplus above the reserve requirement of €921,000.

- The major income streams for ESE were derived from individual and corporate memberships, corporate sponsorship of activities, European Journal of Endocrinology and the ESE Advocacy Representation Scheme. A surplus was also made from Congress activities.

- Costs are rising and there is uncertainty with regards to delegate attendance at conferences (in–person versus online), therefore future surpluses from the Congress are less guaranteed. ESE is also aware that there are increasing pressures on budgets for the endocrine community, which is having an impact, along with an increasing challenge for industry to provide funding for educational activities.

- The major items of expenditure were related to the support of the various activities, including the Congress, grants and awards, policy and advocacy, the member magazines and website, and European Journal of Endocrinology. In addition, ESE had overheads, of which the most significant items related to running its secretariat services for both outsourced and in–house staff.

- Continued investment was made in the growth of our team, our technical infrastructure, and in our policy and advocacy work, with the launch of the first European Hormone Day in May 2022.

- Costs are rising and there is uncertainty with regards to delegate attendance at conferences (in–person versus online), therefore future surpluses from the Congress are less guaranteed. ESE is also aware that there are increasing pressures on budgets for the endocrine community, which is having an impact, along with an increasing challenge for industry to provide funding for educational activities.

- Investments performed poorly in 2022 with a loss of €697,159.

- We continue to retain a Finance Director on a consultancy basis for advice purposes, and our auditor is Moore Kingston Smith, a top 20–rated accountancy firm.

- The ESE trustees are aware that, at the end of 2022, there were funds held above the reserves. They have taken this into account when reviewing the strategy for future years. Investment in specified projects is planned, including a major data integration project which will also allow ESE to bring membership services in–house.

- A careful approach is necessary, due to uncertainties in relation to revenue and rising costs as outlined above. The focus will be on ensuring ESE’s financial stability.

Society finances

We thank everyone for their support during this period. We look forward to continuing to support our endocrine community!

Djuro Macut
Treasurer, ESE
Audited accounts

Revenue

- Sponsorship and grants: €523,189 (12%)
- Congress income: €2,632,330 (61%)
- Annual meetings and events: €87,714 (2%)
- Publications income: €491,969 (11%)
- Membership subscriptions (including corporate): €498,502 (12%)
- Rebates and commissions: €20,123 (0%)
- Investment income: €55,468 (1%)

Total revenue: €4,309,295

Direct costs

- Congress costs: €2,271,461 (62%)
- Clinical and scientific activities: €130,237 (4%)
- Membership: €269,489 (7%)
- Annual meetings and events: €423,069 (12%)
- Communications, media and publicity: €272,352 (7%)
- Publications costs: €135,158 (4%)
- Grants and awards: €158,396 (4%)

Total direct costs: €3,660,162

Gross surplus: €649,133

Overheads

- Staff costs and overheads: €475,999 (47%)
- Cost of trustees’ meetings: €119,118 (12%)
- Legal and professional fees: €71,078 (7%)
- Policy and advocacy: €263,699 (26%)
- Investment manager, audit and accountancy: €44,120 (4%)
- Foreign exchange (gain)/loss: €29,069 (3%)

Total overheads: €1,003,083

Operating surplus/(loss): – €353,950

Other investment (losses)/gains: – €697,159

(Deficit)/surplus on ordinary activities: – €1,051,109
Recognising excellence

Our prestigious grants and awards recognise world-leading scientists and clinicians across the field of endocrinology, while our early career awards provide support for the next generation, to help them achieve their potential. ESE thanks Ipsen for supporting the Geoffrey Harris Award, and Novo Nordisk for supporting the Jens Sandahl Christiansen Award.

**Honorary Membership**

- Clara Alvarez (Spain)
- Barbara Jarzab (Poland)
- Ljiljana Marina (Serbia)
- Camilla Schalin-Jäntti (Finland)
- Bülent Yıldız (Turkey)

**Special Recognition Award**

- Peter Rossing (Denmark)
- Josep Köhrle (Germany)
- Cristina Olarescu (Norway)
- Ruben Nogueiras (Spain)
- Shlomo Melmed (USA)
- George Papadakis (Switzerland)
- Joeri Walravens (Belgium)
- Hamza Benderradji (France)
- Manuel D Gahete (Spain)
- Gloria Elena Silva Román (Mexico)
- Chris Smith (UK)

**European Hormone Medal**

- Roland Stimson (UK)
- Roland Stimson (UK)

**Geoffrey Harris Award**

- AJ van der Lely (The Netherlands)

**European Journal of Endocrinology Award**

- Peter Rossing (Denmark)

**Jens Sandahl Christiansen Award**

- Cristina Olarescu (Norway)
- Ruben Nogueiras (Spain)

**Clinical Endocrinology Trust Award**

- Alberto Pereira (The Netherlands)

**Transatlantic Alliance Award**

- Shlomo Melmed (USA)

**Young Investigator Award winners**

- Barbara Altieri (Germany), Lucas Bouys (France), Ana Carreira (Portugal), Giulia Del Sindaco (Italy), Aristidis Diamantopoulos (Greece), Typhanie Dumontet (USA), Ross Hamblin (UK), Nikolaos Nikolaou (UK), Joris Osinga (The Netherlands), Valeria Pecce (Italy), Carolina Pieterman (The Netherlands) and Louise Ramhøj (Denmark).

**Poster Award winners**

- Clinical posters: Alessandro Maria Berton (Italy), Georgios Papadakis (Switzerland), Giulia Rodari (Italy) and Joeri Walravens (Belgium).
- Basic science/translational posters: Hamza Benderradji (France), Manuel D Gahete (Spain), Gloria Elena Silva Román (Mexico) and Chris Smith (UK).